Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors

4 Dec 2018

Abstract excerpt

Inhibition of poly(ADP-ribose) polymerase (PARP) activity induces synthetic lethality in mutated BRCA1/2 cancers by selectively targeting tumor cells that fail to repair DNA double strand breaks (DSBs). Clinical studies have confirmed the validity of the synthetic lethality approach and four different PARP inhibitors (PARPi; olaparib, rucaparib, niraparib and talazoparib) have been approved as monotherapies for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30518089
DOI: 10.3390/cancers10120487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) InhibitorsPMID 30518089Read ↗

Current status of poly(ADP-ribose) polymerase inhibitors and future directionsSemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.Semantic proximity Read ↗

PARP inhibitors: Synthetic lethality in the clinicSemantic proximity Read ↗

New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.Semantic proximity Read ↗

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistanceSemantic proximity Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity Read ↗

Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisitedSemantic proximity Read ↗

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedsideSemantic proximity Read ↗

Role of PARP Inhibitors in Cancer Biology and TherapySemantic proximity Read ↗

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.